Sergio Giralt

91PUBLICATIONS
421CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMedical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (91)

|Aug 19, 2026
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Jul 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

|Jul 07, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

|Jun 15, 2026
Daratumumab therapy for refractory immune cytopenias after allogeneic hematopoietic cell transplantation.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

Pageof 16

Frequent Collaborators

42 joint publications

Miguel-Angel Perales

36 joint publications

Gunjan Shah

35 joint publications

Heather Landau

28 joint publications

Urvi Shah